3 results
Approved WMOCompleted
The objective of this study is to evaluate the effect of the 4 successive monthly subcutaneous administrations of 30 mg of gevokizumab (in part A) , as well as 60mg (in part B) of the protocol, versus placebo on the reduction of arterial wall…
Approved WMOCompleted
This study aims to investigate the sensitivity and specificity of the history and physical examination for the diagnosis of giant cell arteritis, compared with the superficial temporal artery biopsy, and get more insight into the positive and…
Approved WMOCompleted
The objective of this study is to explore the efficacy and safety of gevokizumab in patients with Schnitzler syndrome.